再者，信银(香港)资本研究部的统计显示，创新药IND、NDA数量在经过2022年低位后重回增长，今年三季度药物临床获批1033个，同比增长25%，1类创新药获批上市共8个，同比翻了一倍。该机构认为，国产创新药正加速进入“新质发展阶段”。What bullish news about biomedical stocks has been announced in the market recently? How do institutions view the subsequent performance of biomedical stocks?
Caixin Media News on November 20th: Today, pharmaceutical stocks in the Hong Kong stock market are favored by funds, with Lekai Pharmaceuticals up nearly 20%, Collin Bio-Tech, and Keji Pharmaceuticals up nearly 12%, and Yimingangke up over 10%.
On the news front, the "2024 Medical Devices Economic Information Release Conference" hosted by the Southern Medical Economic Research Institute of the National Medical Products Administration was held in Jiading, Shanghai on November 18. The conference pointed out the need to deepen the reform of comprehensive life cycle supervision of medical devices, accelerate the cultivation and development of new quality medical device productivity, and better serve the public's health needs.
Furthermore, according to the statistics from the Research Department of Sinolink Capital (Hong Kong), the number of innovative drugs' IND and NDA applications has rebounded after hitting a low point in 2022. In the third quarter of this year, there were 1033 drug clinical approvals, a 25% year-on-year increase. A total of 8 first-class innovative drugs were approved for marketing, doubling compared to the same period last year. The institution believes that domestically developed innovative drugs are accelerating into a "new quality development stage".
Furthermore, at a recent third-quarter earnings conference, WuXi AppTec responded to some questions regarding the progress of legislation and the company's business prospects in the USA. Hu Zhengguo, Vice Director and Global Chief Investment Officer of WuXi AppTec, said: "The Biosafety Law was initiated by this current session of Congress, and the U.S. election did not directly affect the Biosafety Law still in the legislative process. There is still uncertainty about whether this law can be passed during this congressional term."
Institutions believe that the future performance recovery of the CXO is worth looking forward to.
In a recent statement, CICC pointed out that although most companies in the CXO sector still face certain pressures on their mid-year performance in 2024, some companies' orders have started to recover. Combining the situation in the third quarter report, the current trend of order recovery shows sustainability. The improvement in orders initially reflects the recovery of industry prosperity, which will gradually translate into performance. The future performance recovery of CXO is worth looking forward to.
haitong sec also pointed out that against the background of the US interest rate cut, the mild recovery of investment and financing in the biomedical industry has become a certainty trend. As of November 5, 2024, the total amount of overseas biomedical investment and financing has reached $45.3 billion, exceeding the full year of 2023 at $41.7 billion and 2022 at $44.2 billion. Domestic demand side is still bottoming out.
The brokerage believes that the current domestic biomedical investment and financing are still in the stage of policy support. It is expected that the investment of state-owned guided funds, local government finances, the gradual opening up of capital market IPOs and refinancing will gradually reverse the downward trend of biomedical investment and financing.
Editor/Lambor
